Last edition
News about "BRUIN CLL-313 trial"
US FDA Approves Pirtobrutinib for Untreated CLL/SLL
The US FDA has approved Eli Lilly’s pirtobrutinib (Jaypirca) for previously untreated CLL/SLL in adults without known 17p deletion.
BRUIN CLL-313 Trial | 05/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members